Fibrin Modulating Agents
- Fibrin Modulating Agents
- Accession Number
Agents that affect the function of FIBRIN in BLOOD COAGULATION. They are used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.
Drug Drug Description Lepirudin A protein-based direct thrombin inhibitor used as an anticoagulant in patients with heparin-induced thrombocytopenia. Alteplase A recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Reteplase A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Anistreplase A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Tenecteplase A modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Streptokinase A purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism. Ticlopidine A platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA). Tranexamic acid An antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. Ardeparin For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery. Aminocaproic acid An antifibrinolytic agent used to induce clotting postoperatively. Tirofiban A platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome. Phylloquinone A fat soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses. Heparin An anticoagulant indicated for thromboprophylaxis and to treat thrombosis associated with a variety of conditions such as pulmonary embolism and atrial fibrillation. Enoxaparin A low molecular weight heparin used for the prophylaxis of deep vein thrombosis and ischemic complications of unstable angina and non-Q-wave myocardial infarction. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Defibrotide A mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation. Ancrod An anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country. Fibrinolysin Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas. Sulodexide A drug used to treat chronic venous ulcers in the legs. Danaparoid A heparinoid with anticoagulant and antithrombotic activities used for the treatment of acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT. Tinzaparin A low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin. Nadroparin A low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction. Batroxobin No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously. Desirudin Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery. Protein C A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Ozagrel Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes. Sarpogrelate Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic. Nitroaspirin Nitroaspirin has been investigated for the treatment of Intermittent Claudication. Higenamine Higenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects). Brinase Not Annotated Saruplase Not Annotated Fondaparinux An anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction. Monteplase Monteplase has been used in trials studying the treatment of Pulmonary Embolism. Plasminogen Plasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia). Menadione The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification. Cilostazol An antiplatelet agent and vasodilator used for the symptomatic relief of intermittent claudication. Pentaerythritol tetranitrate Used for the treatment of angina pectoris . Semuloparin Investigated for use/treatment in thrombosis. Dalteparin A low molecular weight heparin used for the prophylaxis of thrombotic events in certain patients and prevent acute cardiac ischemic events in patients with unstable angina and non-Q-wave myocardial infarction. Reviparin By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of... Parnaparin A low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis. Eplivanserin Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others. Menaquinone 6 Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2). Menaquinone Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists). Menadione bisulfite Not Annotated
- Drugs & Drug Targets